Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of Baseline Resistance Mutations
- Authors: Abecasis AB, Baele G, Camacho RJ, Gomes P, Pineda-Peña AC, Theys K, Van Laethem K, Vandamme AM
- Publication Year: 2016
- Journal: AIDS Research and Human Retroviruses
- Link: https://www.liebertpub.com/doi/abs/10.1089/aid.2015.0095%20
The latest nonnucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (RPV) is indicated for human immunodeficiency virus type-1 (HIV-1) patients initiating antiretroviral treatment, but the extent of genotypic RPV resistance in treatment-naive patients outside clinical trials is poorly defined. This retrospective observational study of clinical data from Belgium and Portugal evaluates genotypic information from HIV-1 drug-naive patients […]
Read More